Validation of the Adenomyosis Calculator

checkorphan
Learn more about:
Adenomyosis
Related Clinical Trial
Determination of the Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome, or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis The Effect of Adenomoyosis on Pregnancy Outcomes Observational Study of Patients Suffering From Endometriosis and Adenomyosis Factors Associated With Adenomyosis and a Clinical Scoring System for the Diagnosis Quality of Life After Hysterectomy (AdenoQOL) Low Molecular Weight Heparin on the Adenomyosis Patients’IVF-ET Outcome Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI Clinical and Molecular Study of Endometriosis and Adenomyosis Surgical Success After Laparoscopic vs Abdominal Hysterectomy Electronic Catheter Stethoscope Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Uterine Artery Embolization for Symptomatic Fibroids Oxytocin in MRI-HIFU To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Effect of Addition of Steroids on Duration of Analgesia Paracervical Block in Laparoscopic Hysterectomy Use of Dexamethasone in Uterine Artery Embolization Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Dienogest for Treatment of Adenomyotic Uteri Health-Related QoL Among Women Receiving Hysterectomy in NTUH Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis Adenomyosis and Ulipristal Acetate Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis LNG-IUS for Treatment of Dysmenorrhea Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Adenomyosis: Genomic Mechanisms and Biological Response What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis A Prospective Study of Diagnostic Accuracy of Ultrasound Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis A Multi-omics Study of Adenomyosis Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Levonorgestrel Intrauterine System and Adenomyosis Validation of the Adenomyosis Calculator Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Norwegian Adenomyosis Study III: Peristalsis Histopathological Diagnosis of Adenomyosis Norwegian Adenomyosis Study I Vaginal Bromocriptine for Treatment of Adenomyosis Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis

Brief Title

Validation of the Adenomyosis Calculator

Official Title

Prospective Validation of a Prediction Model for Diagnosing Adenomyosis With Ultrasound.

Brief Summary

      Adenomyosis is a disease where ectopic endometrial glands affect the muscular wall of the
      uterus. Women that suffer from dysmenorrhea or infertility caused by adenomyosis need to
      confirm or rule out adenomyosis, and therefore tools for non-histologic confirmation of
      adenomyosis are indubitably required. Transvaginal ultrasound has been shown to be useful in
      diagnosing adenomyosis, but the interpretation of findings requires significant expertise in
      ultrasound and experience with diagnosing adenomyosis. This is because adenomyosis shows a
      very heterogeneous appearance in ultrasound. There are many different diagnostic signs that
      have to be considered and weighed.

      In a previous study, the investigators have developed a diagnostic algorithm that helps
      clinicians diagnose adenomyosis with transvaginal ultrasound and a clinical examination. It
      showed good diagnostic accuracy and seemed to be very robust with regards to artifacts and
      experience of the examiner. It is now necessary to validate this prediction model in a new,
      prospective study so it can be used in clinical practice.

Study Type

Observational

Primary Outcome

Diagnostic accuracy of the prediction model for adenomyosis

Secondary Outcome

 Intraclass correlation coefficient (ICC) between readers

Condition

Adenomyosis

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment

500

Start Date

January 2, 2020

Completion Date

December 2022

Primary Completion Date

June 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Premenopausal (defined by having had menstruation the last six month)

          -  If amenorrhea with levonorgestrel intrauterine device, the woman should be < 45 years
             old

          -  Hysterectomy planned due to a benign condition

          -  Hysterectomy does not require morcellation it is allowed to divide the uterus into 2-3
             pieces, given that the orientation of the specimen is still possible for the
             pathologist)

          -  Written consent is given

          -  Can communicate in Norwegian or English at the Norwegian study sites, and Finnish,
             Swedish or English at the Finnish study site.

        Exclusion Criteria:

          -  Gynecological cancer present at the time of inclusion

          -  Use of gonadotropin-releasing hormone agonist or antagonist within the last 3 months
             prior to the ultrasound evaluation

          -  Prior endometrial ablation or resection

          -  Postmenopausal status or no menstrual bleeding for the last 6 months, or amenorrhea
             with levonorgestrel-intrauterine device and age >45 years.

          -  Need for morcellation of the uterus

Gender

Female

Ages

N/A - 52 Years

Accepts Healthy Volunteers

No

Contacts

Marit Lieng, Phd, +4797793704, [email protected]

Location Countries

Finland

Location Countries

Finland

Administrative Informations

NCT ID

NCT04135118

Organization ID

OUS P360

Responsible Party

Principal Investigator

Study Sponsor

Oslo University Hospital

Collaborators

 The Hospital of Vestfold

Study Sponsor

Marit Lieng, Phd, Principal Investigator, Oslo University Hospital, Oslo, Norway

Verification Date

February 2020